- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01665716
Ovarian Ageing in Type 1 Diabetes Mellitus (OVADIA)
Ovarian Ageing in Type 1 Diabetes Mellitus: the Role of Vascular Factors
In healthy women, early menopause is an event that is associated with the exacerbation of several risk factors of cardiovascular and skeletal disease. The occurrence of an early menopause may have even greater impact in women with type 1 diabetes mellitus (DM-1). A small number of studies has demonstrated that DM-1 patients experience cycle irregularity and menopause at a younger age compared to controls. In addition, initial studies have suggested that also in regular cycling DM-1 women a decreased ovarian reserve status for age is present. The explanation for this early decay in ovarian reserve in DM-1 patients remains unknown. Next to auto immunity, vascular factors may be possible contributors to accelerated ovarian ageing in DM-1 patients.
Confirmation of more accelerated ovarian ageing in DM-1 women is urgently needed in view of the added risk factors outlined above. Also, the mechanisms behind the advanced ovarian ageing, with focus on vascular factors, may shed new light on our understanding of the ovarian ageing process per se.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3508 GA
- University Medical Center Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Part I: Premenopausal women diagnosed with DM-1 older than 18 years and registered at the department for Endocrinology of in several Dutch hospitals.
Reference group: the Scheffer, Van Rooij, De Vet (SRV) cohort of normal fertile Caucasian women (n=250), recruited in the period of 1990 till 2000.
For the substudy concerning EPCs will we recruite a control group of 20 healthy female age-matched controls. We will recruite these women within the UMC Utrecht due to logistic reasons.
Part II: Postmenopausal women diagnosed with DM-1 and registered at the department for Endocrinology of several Dutch hospitals. Reference group:a selection of women from the Prospect-EPIC cohort, who had experienced natural menopause
Description
Inclusion Criteria:
- Patients: females diagnosed with type 1 diabetes mellitus
- Controls: healthy age-matched female controls
Exclusion Criteria:
- Induced menopause: surgical (premenopausal hysterectomy and/or bilateral ovariectomy), chemo- or radiation therapy, ovarian surgery and irregular menstrual cycles.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
OVADIA 1: serum AMH level
Time Frame: Blood withdrawel once at screening
|
Blood withdrawel once at screening
|
|
OVADIA 2: Age at menopause
Time Frame: Assesed once in questionnaire
|
Assesed once in questionnaire
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Frank Broekmans, MD, PhD, UMC Utrecht
Publications and helpful links
General Publications
- de Kat AC, Gremmels H, Verhaar MC, Broekmans FJ, Yarde F. Early Vascular Damage in Young Women with DM-1 and Its Relation to Anti-Mullerian Hormone: A Cross-Sectional Study. Int J Endocrinol. 2016;2016:1487051. doi: 10.1155/2016/1487051. Epub 2016 Aug 29.
- Yarde F, van der Schouw YT, de Valk HW, Franx A, Eijkemans MJ, Spiering W, Broekmans FJ; OVADIA study group. Age at menopause in women with type 1 diabetes mellitus: the OVADIA study. Hum Reprod. 2015 Feb;30(2):441-6. doi: 10.1093/humrep/deu327. Epub 2014 Dec 1.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL32242.041.10
- 10-345 (Other Identifier: Medical Ethics Committee UMC Utrecht)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's Hospital...RecruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes MellitusIraq, Pakistan
-
Lund UniversityEnrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 DiabetesSweden
-
Superior UniversityActive, not recruitingType 2 Diabetes Mellitus 1Pakistan
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Immunocore LtdNot yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Abdullah KarsNot yet recruitingType 1 Diabetes Mellitus | Autoimmune Diabetes | Type 1 Diabetes Mellitus (T1DM)Turkey (Türkiye)
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States